Research advances in immunotherapy for hepatocellular carcinoma
10.3969/j.issn.1001-5256.2023.05.031
- VernacularTitle:肝细胞癌免疫治疗研究进展
- Author:
Lizhen ZHU
1
,
2
;
Xiaolei XU
2
,
3
;
Xiaojuan WANG
4
;
Hu ZHOU
2
,
3
;
Rui TANG
4
;
Haining FAN
2
;
Qian LU
2
,
3
,
4
Author Information
1. Graduate School of Qinghai University, Xining 810001, China
2. Department of Hepatopancreatobiliary Surgery, The Affiliated Hospital of Qinghai University, Xining 810000, China
3. School of Clinical Medicine, Tsinghua University, Beijing 100000, China
4. Hepato-Pancreato-Biliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
- Collective Name:Hepato-Pancreato-Biliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
- Publication Type:Review
- Keywords:
Carcinoma, Hepatocellular;
Immunotherapy;
Molecular Targeted Therapy
- From:
Journal of Clinical Hepatology
2023;39(5):1197-1203
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) has an insidious onset, and most patients are in the advanced stage when attending the hospital and thus lose the opportunity for radical surgical resection, which results in the poor prognosis of patients. With the development of clinical treatment, the treatment of advanced HCC has gradually transitioned from the relatively single and limited treatment options in the past to the new model of comprehensive treatment. In recent years, immunotherapy, represented by immune checkpoint inhibitors (ICIs), has become widely used in clinical practice. At present, a number of clinical studies have been conducted for immunotherapy combined with local and targeted antitumor therapy, and in particular, ICIs combined with targeted therapy have become a research hotspot in the field of HCC treatment. This article reviews the research advances in immunotherapy for the treatment of HCC.
